PMID- 11156723
OWN - NLM
STAT- MEDLINE
DCOM- 20010208
LR  - 20181130
IS  - 1042-3931 (Print)
IS  - 1042-3931 (Linking)
VI  - 12 Suppl E
DP  - 2000 Dec
TI  - Combining low-molecular-weight heparin and glycoprotein IIb/IIIa antagonists for 
      the treatment of acute coronary syndromes: the NICE 3 story. National 
      Investigators Collaborating on Enoxaparin.
PG  - E10-3;discussion E25-8
AB  - In recent years, a number of new therapies have become available that have 
      significantly improved the care of patients with acute coronary syndromes (ACS). 
      A number of studies have documented the significant superiority of the 
      low-molecular-weight heparin (LMWH), enoxaparin, over unfractionated heparin 
      (UFH) in the treatment of ACS. However, there are insufficient data regarding the 
      safety of using LMWH in combination with glycoprotein (GP) IIb/IIIa antagonists. 
      The NICE 3 study is an open-labeled, non-randomized, observational study 
      examining the feasibility, safety, and preliminary efficacy of the LMWH, 
      enoxaparin, in combination with each of the three commercially available GP 
      IIb/IIIa antagonists in ACS patients. Approximately 600 patients at 45 clinical 
      centers in North America will be divided between the three arms of the trial, 
      representing each of the three GP IIb/IIIa antagonists. Once therapy is 
      initiated, patients will receive no UFH (unless they require a coronary artery 
      bypass graft) and will continue treatment even if invasive cath lab procedures 
      are necessary. NICE 3 builds on the previous experiences of NICE 1 and NICE 4 
      with LMWH in the cath lab (with or without GP IIb/IIIa antagonists) to more 
      aggressively extend the use of LMWHs into the medical management of ACS patients.
FAU - Ferguson, J J
AU  - Ferguson JJ
AD  - Cardiology Research, St. Luke's Episcopal Hospital, Houston, TX 77225, USA. 
      jferguson@heart.thi.tmc.edu
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PL  - United States
TA  - J Invasive Cardiol
JT  - The Journal of invasive cardiology
JID - 8917477
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Anticoagulants)
RN  - 0 (Enoxaparin)
RN  - 0 (Immunoglobulin Fab Fragments)
RN  - 0 (Peptides)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - 42HK56048U (Tyrosine)
RN  - GGX234SI5H (Tirofiban)
RN  - NA8320J834 (Eptifibatide)
RN  - X85G7936GV (Abciximab)
SB  - IM
MH  - Abciximab
MH  - Acute Disease
MH  - Antibodies, Monoclonal/administration & dosage
MH  - Anticoagulants/*administration & dosage
MH  - Coronary Disease/*drug therapy
MH  - Drug Therapy, Combination
MH  - Enoxaparin/*administration & dosage
MH  - Eptifibatide
MH  - Feasibility Studies
MH  - Humans
MH  - Immunoglobulin Fab Fragments/administration & dosage
MH  - Injections, Intravenous
MH  - North America
MH  - Peptides/administration & dosage
MH  - Platelet Aggregation Inhibitors/*administration & dosage
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/*antagonists & inhibitors
MH  - Safety
MH  - Tirofiban
MH  - Tyrosine/administration & dosage/*analogs & derivatives
EDAT- 2001/01/13 11:00
MHDA- 2001/03/03 10:01
CRDT- 2001/01/13 11:00
PHST- 2001/01/13 11:00 [pubmed]
PHST- 2001/03/03 10:01 [medline]
PHST- 2001/01/13 11:00 [entrez]
PST - ppublish
SO  - J Invasive Cardiol. 2000 Dec;12 Suppl E:E10-3;discussion E25-8.